A comprehensive study on drug-related Raynaud’s phenomenon based on the FDA adverse event reporting system

Raynaud’s phenomenon (RP) is often an overlooked adverse event, mainly secondary RP, where drug induction or exacerbation is a controllable and preventable factor. This study aimed to systematically evaluate the association between drugs and RP using the FDA adverse event reporting system (FAERS) database. Utilizing disproportionality analysis, we quantified the risk of RP-associated drugs based on large-scale FAERS case data. Drugs were categorized by ATC classification, and descriptive…

via https://pubmed.ncbi.nlm.nih.gov/40890234/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1HYeX0emtvYgH07Wkz0a8n9otrdMd-JIklc_uo0I5vh1u9WMEy&fc=None&ff=20250903010805&v=2.18.0.post9+e462414